Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.42 |
| ▸ | CA1 | P00915 | 12/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 9/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA7 | P43166 | 4/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.31 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10967045 | 0.89 | CA1 (0.39) | CA2CA1TSHRUSP2CA9 | |
| SCHEMBL12624 | 0.80 | — | — | |
| SCHEMBL18498464 | 0.80 | CA1 (0.33) | CA2CA1CYP3A4 | |
| SCHEMBL921047 | 0.80 | CA2 (0.40) | CA2CA1TSHRUSP2CA9 | |
| SCHEMBL10642894 | 0.78 | — | — | |
| SCHEMBL9421136 | 0.77 | — | — | |
| Ethane SCHEMBL28997522 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL384346 | 0.77 | — | — | |
| SCHEMBL27990047 | 0.77 | — | — | |
| Water SCHEMBL28081744 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3388425-A1 | AMINOAZOLE DERIVATIVE | Teijin Pharma Limited (JP) | 2018-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | CA2 1404/4885CA1 1484/4885TSHR 59/4885 |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | AR, NR3C2, NR5A1 | CA2 1404/4885CA1 1484/4885TSHR 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.